LFMDNov 17, 2025-13.53% since signalLifeMD Stock Plummets After Q3 Earnings: Here's WhyLFMD missed Q3 revenue and adjusted EPS estimates. Company cut fiscal 2025 revenue guidance sharply to $192–193M. Q3 revenue rose 13% YoY to $60.2M; adjusted EBITDA increased 20%. Paid off all outstanding debt; CEO cited GLP‑1 price competition.View signal analysis →
LFMDSep 30, 2025+4.70% since signalLifeMD to offer Novo's Ozempic at $499 per month to eligible US cash-paying customersLifeMD partners with Novo Nordisk to offer Ozempic for $499/month. This will help eligible U.S. patients accessing diabetes treatment.View signal analysis →
